Search

Search results

375 results found

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

Kimball, A B, J M Sobell, C C Zouboulis, Y Gu, D A Williams, M Sundaram, H D Teixeira, and G B E Jemec. 2016. “HiSCR (Hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients With Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2 Adalimumab Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 30 (6): 989-94.

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.

Prens, Errol P, Aida M Lugo-Somolinos, Amy S Paller, Francisco Kerdel, Yinghui Duan, Henrique D Teixeira, Michelle Longcore, and Alexa B Kimball. 2020. “Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.”. American Journal of Clinical Dermatology 21 (4): 579-90.